KEAP1 and non-small cell lung carcinoma: In an exploratory analysis by Skoulidis et al., the activity of sotorasib was observed across a spectrum of prevalent co-occurring mutations, including STK11 and KEAP1, both of which are related to inferior treatment outcomes and a poor prognosis in patients with NSCLC (110, 117, 120, 144–147).